New guidance: infant and follow-on formula from protein hydrolysates
New guidance published by EFSA will assist applicants in preparing and presenting dossiers for authorisation of infant and/or follow-on formulae manufactured from protein hydrolysates. It will also help applicants in preparing dossiers to assess a product’s efficacy in reducing the risk of infants becoming allergic to milk proteins.
Regulatory rules dating back to 2006 were revised in 2016. The revision was based on scientific advice by EFSA on the need to establish the safety and suitability of each protein hydrolysate used in the manufacture of formula. EFSA had also advised that clinical studies be conducted to demonstrate a formula’s potential to reduce the risk of infants developing allergy to milk proteins.
What kind of data do applicants need to submit?
EFSA’s technical and scientific guidance details the type of data and information applicants need to provide. The required information should include:
- Characterisation of the hydrolysed infant or follow-on formulae, including a description of the manufacturing process;
- Information about the nutritional safety and suitability of the formula, including information on the history of use; and/or
- Information on the product’s efficacy in reducing the risk of developing an allergy to milk proteins.
The guidance presents a common format for the organisation of the information applicants need to provide. A well-structured application will help the Scientific Panel on Dietetic Products, Nutrition and Allergies (NDA Panel) to carry out its evaluation and deliver its scientific advice effectively and consistently.
Prior to finalising the guidance, EFSA presented the document to the public and invited feedback. EFSA received and considered over 80 comments from seven interested parties including a governmental organisation, food business operators and industry associations.
What is protein hydrolysate formula?
Formulas manufactured from protein hydrolysates contain protein which has been partially broken down to different degrees with the aim of reducing the risk of infants developing allergies.
Latest News from
EC opens in-depth investigation into proposed acquisition of Monsanto by Bayer23/08/2017 11:20:00
The EC has opened an in-depth investigation to assess the proposed acquisition of Monsanto by Bayer under the EU Merger Regulation. The EC has concerns that the merger may reduce competition in areas such as pesticides, seeds and traits.
Tick and flea control agent Bravecto continues to be acceptably safe to use18/08/2017 13:20:00
New adverse reaction to be included in package leaflet
Trend of converging working time across 28 EU Member States has stalled18/08/2017 12:20:00
The difference in working time between workers in the 28 EU Member States remains large and is especially marked between the ‘older’ 15 EU Member States and the 13 new Member States that joined the EU since 2004, according to new research from Eurofound.
European Solidarity Corps: First volunteers in Italy to help rebuild earthquake-hit regions18/08/2017 11:20:00
The first group of European Solidarity Corps volunteers is arriving in Norcia, Italy, to help with the ongoing efforts to repair damage and rebuild social services for the local community affected by the severe earthquakes that hit the region a year ago.